Masarapu, Yuvarani http://orcid.org/0000-0002-3267-2085
Cekanaviciute, Egle http://orcid.org/0000-0003-3306-1806
Andrusivova, Zaneta
Westholm, Jakub O. http://orcid.org/0000-0002-6849-6220
Björklund, Åsa http://orcid.org/0000-0003-2224-7090
Fallegger, Robin http://orcid.org/0000-0003-3264-6028
Badia-i-Mompel, Pau http://orcid.org/0000-0002-1004-3923
Boyko, Valery http://orcid.org/0000-0002-3724-9294
Vasisht, Shubha
Saravia-Butler, Amanda
Gebre, Samrawit
Lázár, Enikő http://orcid.org/0000-0001-8664-7531
Graziano, Marta
Frapard, Solène http://orcid.org/0000-0002-2649-7225
Hinshaw, Robert G. http://orcid.org/0000-0003-0060-7753
Bergmann, Olaf http://orcid.org/0000-0003-1065-4107
Taylor, Deanne M. http://orcid.org/0000-0002-3302-4610
Wallace, Douglas C. http://orcid.org/0000-0002-7480-8278
Sylvén, Christer
Meletis, Konstantinos http://orcid.org/0000-0001-5665-4781
Saez-Rodriguez, Julio http://orcid.org/0000-0002-8552-8976
Galazka, Jonathan M. http://orcid.org/0000-0002-4153-0249
Costes, Sylvain V. http://orcid.org/0000-0002-8542-2389
Giacomello, Stefania http://orcid.org/0000-0003-0738-1574
Article History
Received: 23 May 2023
Accepted: 17 May 2024
First Online: 11 June 2024
Competing interests
: ZA, SF and SG are scientific advisors to 10x Genomics Inc, which holds IP rights to the ST technology. SG holds 10X Genomics stocks. JSR reports funding from GSK, Pfizer and Sanofi and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Owkin, Pfizer and Grunenthal. All other authors declare no competing interests.